Quest Magazine

Iplex on Hold

Jury Still Out on Value of Vitamin C in CMT1A

A recent trial has shown inconclusive results from various doses of vitamin C (ascorbic acid) in patients with the peripheral nerve disease type 1A Charcot-Marie-Tooth disease (CMT1A), and the jury remains out on this form of treatment, says Michael Shy, an MDA grantee at Wayne State University in Detroit.

ALS: Riding for Augie

Many fundraising events for Augie’s Quest (MDA’s aggressive ALS research initiative) tend to be glamorous galas attracting high-profile socialites to genteel settings.

There was nothing genteel about the fundraiser that began June 20 as part of Race Across America (RAAM). It’s one of the toughest endurance events in the world. Cyclists – usually 250 or so, solo or in teams – race 3,000 miles from Oceanside, Calif., to Annapolis, Md. Four-person teams typically cover that distance in five to eight days of nightmarish physical challenge.

Genetics: You, Me and PGD

Update 5/21/12:This study is closed, and results are available at Decision Making About PGD Is Complex, Study Finds. Information about future studies will be posted at PGD: Couples' Decision Making when available.

Preimplantation genetic diagnosis (PGD) is a way for couples to avoid passing along a hereditary disease to their offspring by pre-screening embryos.

Conference Focuses on Becker MD

An MDA-supported conference for families and professionals interested in scientific, medical and social issues related to Becker muscular dystrophy (BMD) will take place Aug. 1, 2009, at Massachusetts General Hospital in Boston.

The one-day conference is free, but seating is limited and attendees must register by July 24.

The program features:

MMD Research: 'Bright' Prospect

Researchers at the University of Rochester (N.Y.) Wellstone Muscular Dystrophy Cooperative Research Center have identified a compound that has the potential to be developed into a treatment for type 1 myotonic dystrophy (MMD1, or DM1).

The compound, dubbed CAG25, is an "antisense oligonucleotide," a type of construct that's been used to block disease-causing genetic instructions in laboratory experiments and human trials in other diseases.

Conference Focuses on Becker MD

An MDA-supported conference for families and professionals interested in scientific, medical and social issues related to Becker muscular dystrophy (BMD) will take place Aug. 1, 2009, at Massachusetts General Hospital in Boston.

The one-day conference is free, but seating is limited and attendees must register by July 24.

The program features:

ALS Research: No Smoking Gun

A new meta-analysis combining data from 11 studies has found no connection between variations in genes for paraoxonase (PON) enzymes and an increased risk of developing amyotrophic lateral sclerosis (ALS).

ALS Research: No Smoking Gun

 

A new meta-analysis combining data from 11 studies has found no connection between variations in genes for paraoxonase (PON) enzymes and an increased risk of developing amyotrophic lateral sclerosis (ALS).

“Show me the money!” MDA greenlights grants

At a time when federal and private funds for biomedical research have become scarce, the Muscular Dystrophy Association reasserts its leadership in the fight against muscle diseases by announcing grants to innovative research projects throughout America and in Canada.

“Federal support for the type of work we do has just about dried up, especially in the current economic climate.  Simply put, without the support of MDA, this line of investigation could not be pursued by our lab,” said Eric Schon, researcher at Columbia University Medical Center in New York.

Pages